OX338 - Moderate to moderately severe pain
|Indication||Moderate to moderately severe pain|
|Development phase||Finalized phase 1|
|Expected filing with FDA||-|
|In-house or partnership||In-house|
Opioids are still used unnecessarily in many situations, further fueling the opioid crisis.
Based on Orexo´s novel oral formulation technology, the aim is to develop an opioid-level pain relief treatment for short-term pain (up to 5 days) without the risk of addiction.
Results from the exploratory PK-study in healthy volunteers showed significant better PK-profile, such as faster uptake and higher peak, when compared to nasal spray available on the market.